Urgent

Nephrotic syndrome — oedema, proteinuria, hypoalbuminaemia (adult)

Glomerular disease · Renal / Electrolyte
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Triad of heavy proteinuria (>3.5 g/day or PCR >300-350 mg/mmol / ACR >220), hypoalbuminaemia (<30 g/L) and oedema, usually with hyperlipidaemia and lipiduria. Reflects podocyte/GBM injury: in adults commonly membranous nephropathy, FSGS, minimal change, diabetic nephropathy, amyloid/myeloma, or lupus/membranoproliferative patterns. Key ED priorities are managing oedema safely, recognising and preventing thromboembolism (loss of antithrombin), treating infection risk, and arranging biopsy-directed specific therapy.

Red flags

  • Pleuritic chest pain/dyspnoea (PE), unilateral loin pain + haematuria + GFR fall (renal vein thrombosis) — image and anticoagulate
  • Fever, abdominal pain, cellulitis or signs of sepsis — nephrotic patients are functionally immunosuppressed (SBP, pneumococcal infection)
  • Rapidly rising creatinine, hypertension, active sediment/RBC casts — mixed nephritic/RPGN picture needing urgent biopsy
  • Anasarca with hypotension/AKI from aggressive diuresis
  • Haemoptysis, rash, systemic illness — secondary/systemic disease

Assessment

Differential diagnosis

  • Minimal change disease (abrupt, steroid-responsive; commonest in children)
  • Focal segmental glomerulosclerosis (FSGS)
  • Membranous nephropathy (anti-PLA2R; highest VTE risk)
  • Diabetic kidney disease (long-standing DM, retinopathy)
  • Amyloidosis / myeloma / monoclonal gammopathy
  • Lupus nephritis (class V), membranoproliferative GN, HBV/HCV/HIV-associated
  • Non-renal oedema: cardiac failure, cirrhosis, venous/lymphatic, drug-induced

Investigations

  • Quantify proteinuria: urine PCR or ACR (spot) and/or 24-h protein; urine microscopy (oval fat bodies, fatty/lipid casts, assess for RBC casts suggesting mixed nephritic picture)
  • Serum albumin, U&E/creatinine/eGFR, lipid profile, LFTs
  • Immunology: ANA/dsDNA, complement C3/C4, anti-PLA2R (membranous), ANCA/anti-GBM if nephritic features; HBV/HCV/HIV serology
  • Serum + urine protein electrophoresis / free light chains (myeloma, amyloid)
  • HbA1c/fundoscopy if diabetes suspected; renal ultrasound
  • Renal biopsy in adults (definitive diagnosis) unless clearly diabetic with typical course — arrange via nephrology
  • If features of VTE: Doppler/CTPA; renal vein thrombosis imaging if flank pain/haematuria/sudden GFR fall (esp. membranous)

Management

  • Confirm nephrotic (not nephritic) and exclude secondary causes (diabetes, myeloma/amyloid, lupus, infection, drugs)
  • Manage oedema: dietary sodium restriction (<2 g sodium/day) and fluid moderation; loop diuretic titrated to gentle weight loss ~0.5-1 kg/day (avoid overdiuresis -> hypovolaemia/AKI/thrombosis)
  • Start anti-proteinuric/renoprotective ACEi or ARB once haemodynamically stable (reduces proteinuria, BP control)
  • Assess VTE risk and consider prophylactic anticoagulation when serum albumin is low (commonly <20-25 g/L, especially membranous nephropathy) and bleeding risk acceptable
  • Statin for nephrotic hyperlipidaemia; treat/vaccinate against infection risk (pneumococcal), high index of suspicion for spontaneous bacterial peritonitis/cellulitis
  • Refer to nephrology for biopsy and disease-specific immunosuppression (e.g. corticosteroids for minimal change; risk-based rituximab/CNI for membranous; immunosuppression for FSGS/lupus)
  • Monitor U&E, albumin, weight, BP and for AKI (overdiuresis, renal vein thrombosis, AIN, progression)

Drugs & doses

Furosemide 40-80 mg PO/IV once-twice daily, titrate to weight loss ~0.5-1 kg/day; add thiazide (metolazone 2.5-5 mg PO) for diuretic resistance with close monitoring [verify local dose]
Ramipril 2.5-10 mg PO once daily OR losartan 50-100 mg PO once daily (anti-proteinuric; monitor K+/creatinine) [verify local dose]
Atorvastatin 20-40 mg PO once daily for hyperlipidaemia
Prophylactic anticoagulation when albumin low (e.g. <20-25 g/L) and bleeding risk acceptable: LMWH (enoxaparin 40 mg SC once daily) or warfarin (target INR 2-3); DOACs emerging but less evidence [verify local dose]
Therapeutic anticoagulation if confirmed VTE/renal vein thrombosis (LMWH then warfarin/DOAC) [verify local dose]
Pneumococcal vaccination; treat intercurrent infection promptly (empirical cover per source)
Disease-specific immunosuppression (steroids/rituximab/CNI/cyclophosphamide) initiated by nephrology after biopsy [verify local dose]

Disposition

Admit if severe oedema/anasarca, AKI, suspected/confirmed thromboembolism, infection, or new diagnosis needing urgent biopsy. Otherwise rapid nephrology referral for biopsy and disease-specific therapy; outpatient diuretic titration with close monitoring of weight, U&E and albumin.

Complications & pitfalls

  • Venous and arterial thromboembolism (DVT/PE, renal vein thrombosis) from urinary antithrombin loss
  • Infection (pneumococcal peritonitis/cellulitis/sepsis) from immunoglobulin loss
  • AKI (intravascular depletion, overdiuresis, renal vein thrombosis, superimposed AIN)
  • Accelerated atherosclerosis/hyperlipidaemia; protein malnutrition
  • Progression to CKD/kidney failure depending on underlying lesion

Exam pearls

  • Thrombosis risk rises steeply as albumin falls (greatest <~28 g/L; membranous nephropathy carries the highest risk) — weigh prophylactic anticoagulation against bleeding when albumin is markedly low [verify local threshold].
  • Hypoalbuminaemia makes warfarin handling unpredictable (increased free drug) — monitor INR closely and consider LMWH.
  • Spontaneous bacterial peritonitis and pneumococcal sepsis are classic 'can't miss' complications — low threshold for cultures and empirical antibiotics, and vaccinate.
  • Diurese gently: aggressive loop diuresis in an intravascularly deplete nephrotic patient precipitates AKI and thrombosis.
  • In adults, biopsy drives therapy — do not commit to steroids before histology except where a clear secondary cause (e.g. diabetes) is established.

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.